Thota Ganesh1, Jianxiong Jiang2, Ray Dingledine2. 1. Department of Pharmacology, School of Medicine, Emory University, 1510 Clifton Rd, Atlanta, GA 30322, USA. Electronic address: tganesh@emory.edu. 2. Department of Pharmacology, School of Medicine, Emory University, 1510 Clifton Rd, Atlanta, GA 30322, USA.
Abstract
EP2 receptor has emerged as an important biological target for therapeutic intervention. In particular, it has been shown to exacerbate disease progression of a variety of CNS and peripheral diseases. Deletion of the EP2 receptor in mouse models recapitulates several features of the COX-2 inhibition, thus presenting a new avenue for anti-inflammatory therapy which could bypass some of the adverse side effects observed by the COX-2 inhibition therapy. We have recently reported a cinnamic amide class of EP2 antagonists with high potency, but these compounds exhibited a moderate selectivity against prostanoid receptor DP1. Moreover they possess acrylamide moiety in the structure, which may result in liver toxicity over longer period of use in a chronic disease model. Thus, we now developed a second generation compounds that devoid of the acrylamide functionality and possess high potency and improved (>1000-fold) selectivity to EP2 over other prostanoid receptors.
EP2 receptor has emerged as an important biological target for therapeutic intervention. In particular, it has been shown to exacerbate disease progression of a variety of CNS and n class="Disease">peripheral diseases. Deletion of the EP2 receptor in mouse models recapitulates several features of the COX-2 inhibition, thus presenting a new avenue for anti-inflammatory therapy which could bypass some of the adverse side effects observed by the COX-2 inhibition therapy. We have recently reported a cinnamic amide class of EP2 antagonists with high potency, but these compounds exhibited a moderate selectivity against prostanoid receptor DP1. Moreover they possess acrylamide moiety in the structure, which may result in liver toxicity over longer period of use in a chronic disease model. Thus, we now developed a second generation compounds that devoid of the acrylamide functionality and possess high potency and improved (>1000-fold) selectivity to EP2 over other prostanoid receptors.
Authors: H Hizaki; E Segi; Y Sugimoto; M Hirose; T Saji; F Ushikubi; T Matsuoka; Y Noda; T Tanaka; N Yoshida; S Narumiya; A Ichikawa Journal: Proc Natl Acad Sci U S A Date: 1999-08-31 Impact factor: 11.205
Authors: Karine M Egan; John A Lawson; Susanne Fries; Beverley Koller; Daniel J Rader; Emer M Smyth; Garret A Fitzgerald Journal: Science Date: 2004-11-18 Impact factor: 47.728
Authors: Annavarapu Hari Kishore; Hanquan Liang; Mohammed Kanchwala; Chao Xing; Thota Ganesh; Yucel Akgul; Bruce Posner; Joseph M Ready; Sanford D Markowitz; Ruth Ann Word Journal: Proc Natl Acad Sci U S A Date: 2017-07-17 Impact factor: 11.205
Authors: Eleonora Aronica; Sebastian Bauer; Yuri Bozzi; Matteo Caleo; Raymond Dingledine; Jan A Gorter; David C Henshall; Daniela Kaufer; Sookyong Koh; Wolfgang Löscher; Jean-Pierre Louboutin; Michele Mishto; Braxton A Norwood; Eleonora Palma; Michael O Poulter; Gaetano Terrone; Annamaria Vezzani; Rafal M Kaminski Journal: Epilepsia Date: 2017-07 Impact factor: 5.864